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Abstract Monocyte chemoattractant protein-1 (MCP-1) plays 
an important role in the recruitment of monocytic ells to the site 
of inflammation. Resting mesangial cells express barely detecta- 
ble levels of MCP-I mRNA. Treatment of rat mesangial cells 
with platelet products PDGF-AB, PDGF-BB or serotonin tran- 
siently induced MCP-1 expression with a maximum after 2 to 4 
h and a decline to baseline after 6 to 8 h. Different kinetics were 
observed with interleukin-li~ (IL-I/]), which induced a long last- 
ing elevation of MCP-1 mRNA for more than 20 h. Together, 
PDGF and IL-11~ synergistically induced MCP-I expression. 
The effect was most obvious after 16 to 20 h, when induction by 
PDGF alone had already faded, but still PDGF strongly en- 
hanced IL-li~-induced MCP-1 mRNA expression. MCP-1 
mRNA levels were regulated by changes in the stability of the 
mRNA: inhibition of protein synthesis by cycloheximide by itseff 
induced MCP-1 mRNA expression and led to superinduction in 
the presence of PDGF. Message stabilization also contributed to 
the synergistic action of PDGF and IL-I~: the apparent half life 
of MCP-1 mRNA determined in the presence of actinomycin D 
was prolonged when both stimuli were added together. We could 
thus show that in mesangial cells different types of cytokines and 
growth factors synergize to enhance MCP-1, the secretion of 
which could lead to the recruitment of monocytic cells into the 
inflamed mesangium. 
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1. Introduction 
Monocyte chemoattractant protein-1 (MCP-1) was origi- 
nally characterized as a gene (JE) induced by platelet-derived 
growth factor (PDGF) in mouse fibroblasts [1,2]. Since then, 
it was shown that MCP-1 is a potent chemokine with consider- 
able specificity for monocytes [3]. It is expressed in many differ- 
ent cell types besides fibroblasts uch as endothelial cells, vascu- 
lar smooth muscle cells, osteoblastic ells, mesangial cells or 
monocytes themselves. 
Enhanced expression of the protein was observed in vivo in 
different models of inflammation and injury in which infiltra- 
tion of monocytic ells was observed (e.g. [4,5]). In the kidney, 
MCP-1 expression was enhanced in different animal models of 
experimental glomerular nephritis (e.g. [6-9]). Glomerular 
MCP-1 was also detectable in biopsies from patients with in- 
flammatory or proliferative glomerulonephritis [9]. The in vivo 
localization of MCP-1 suggested that glomerular mesangial 
*Corresponding author. Fax: (49) (9131) 85 92 02. 
cells might be a source of MCP-1, not excluding other cell types 
such as epithelial cells and infiltrating monocytes. 
Platelet-derived growth factor (PDGF), the stimulus which 
led to the detection of MCP-1 activity, was recently shown to 
play a predominant role in glomerulonephritis [10,11]. In the 
model of anti-thymocyte antibody-induced glomerulonephritis 
[6], MCP-I was found to be enhanced in an early phase, which 
might relate to the effect of immune complexes, but it was also 
elevated at a later time period, when both PDGF and inter- 
leukin-1 (IL-1) levels were known to be increased. 
Given its functional role as chemoattractant, investigations 
have focussed on the regulation of MCP-1 expression by in- 
flammation-related cytokines uch as IL-1, tumor necrosis fac- 
tor c~ (TNF~) or interferon 7. In mesangial cells, IL-I and 
TNFc~ are the most potent stimuli investigated so far [12-14]. 
In order to get a further insight into the regulation of MCP-1 
expression during glomerular inflammation, we investigated 
the mechanism of MCP-1 mRNA expression by PDGF and 
IL-lfl in cultured mesangial cells. 
2. Materials and methods 
2.1. Materials 
Cell culture media consisted of Dulbecco's modified Eagle's medium 
(DMEM), L-glutamine, penicillin and streptomycin (Biochrom), fetal 
calf serum (Gibco) and bovine insulin (Sigma). Recombinant human 
platelet-derived growth factors (rhPDGF-AA, -AB and -BB) were 
kindly provided by J. Hoppe (Biozentrum Wtirzburg, Germany). 
Recombinant human IL-lfl (5x 10 v U/mg) was obtained from 
Boehringer. 
2.2. Cell culture 
Rat mesangial cells were isolated and cultured as previously de- 
scribed [15]. Cells were g own in DMEM (supplemented with 2 mM 
L-glutamine, 5 ¢tg/ml insulin, 100 U/ml penicillin and 100/tg/ml strepto- 
mycin) containing 10% FCS. Before stimulation, the cells were growth- 
arrested by serum deprivation for 3 days in DMEM containing 0.5% 
FCS. For the experiments cells were used between passages 10 and 25. 
2.3. Northern blot analysis 
Analysis of mRNA expression was performed as previously de- 
scribed [16]. Total RNA was extracted according to the protocol of 
Chomczynski and Sacchi [17] with minor alterations. RNA yield usu- 
ally was 30-40 ¢tg/Petri dish. 
Separation of total RNA (10/lg/lane) was achieved by use of 1.2% 
agarose gels containing 2% (v/v) formaldehyde with 1 x MOPS as gel/ 
running buffer. Separated RNA was transferred to nylon membranes 
by capillary blotting. Hybridization was performed with cDNA probes 
labeled with [32P]dCTP using the Megaprime random prime labeling kit 
(Amersham). A cDNA probe specific for GAPDH was obtained as 
reverse transcribed DNA amplified by polymerase chain reaction as 
described [18]. A cDNA probe specific for rat MCP-I was kindly pro- 
vided by Dr. T. Yoshimura (NCI, Frederick, MD) [19]. A eDNA probe 
for the inducible cyclooxygenase (PGHS-2) was kindly provided by D. 
DeWitt (Michigan State University, MI) [20]. 
DNA/RNA hybrids were detected byautoradiography using Kodak 
X-OMAT AR film; exposure time ranged between 1 and 6 days. Quan- 
titative analysis was performed by densitometric s anning of the au- 
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toradiographs (Bioprofil, Fr6bel, Germany). All values were corrected 
for differences of RNA loading by calculating the ratio of MCP-I or 
PGHS-2 to GAPDH expression or ethidium bromide fluorescence of
28S rRNA. 
3. Results 
3.1. MCP-1 mRNA expression i  mesangial cells: induction by 
PDGF isoforms and serotonin 
Basal levels of MCP-1 mRNA were very low in growth- 
arrested and cycling mesangial cells. Ongoing transcriptional 
activity became vident, when the cells were incubated in the 
presence of the inhibitor of protein synthesis cycloheximide 
(CHX; Fig. 1). CHX (10 pg/ml) rapidly enhanced the steady 
state levels of MCP-1 mRNA within 1 to 2 h. Elevated levels 
then persisted for several h. PDGF-AB and -BB in the concen- 
tration range of 5 to 50 ng/ml induced MCP-1 mRNA (Fig. 2), 
whereas PDGF-AA was without effect. No significant differ- 
ence was observed between the two active isoforms. Induction 
of MPC-1 mRNA expression was transient, peaked at about 
2 to 4 h and declined thereafter. Examples are shown in Figs. 
1 and Fig. 4. In the presence of CHX, PDGF led to increasing 
superinduction f MCP-1 mRNA during the period measured 
(up to 6 h). Qualitatively the same results were obtained when 
serotonin (5-HT), another factor released from activated plate- 
lets, was used as stimulus (data not shown). 
3.2. EfJect of lL-lfl plus PDGF on MCP-1 mRNA expression 
As compared with PDGF or 5-HT, IL-lfl induction of MCP- 
1 mRNA followed different kinetics. A continuous increase in 
mRNA levels was observed for 6 to 8 h and these increased 
levels persisted for at least 24 h (Figs. 3, 4). IL-lfl was a potent 
inducer of MCP-1 mRNA in cycling and growth-arrested me- 
sangial cells in the presence and absence of serum. PDGF in 
contrast, was more effective in serum-reduced cultures (0.5% 
serum). 
Coincubation of mesangial cells with IL-lfl and PDGF re- 
sulted in an enhanced MCP-1 mRNA expression. During the 
early phase, MCP-I mRNA elevation was just additive. At later 
time points, when the induction of MCP-1 mRNA by PDGF 
declined, the elevated levels in cells coincubated with PDGF 
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Fig. 1. Induction of MCP- 1 mRNA by PDGF and CHX mesangial cells 
were incubated with CHX (©, 10/lg/ml), PDGF-AB (n, 20 ng/ml) or 
both compounds (o) for the times (h) indicated. Northern blot analyses 
were performed asdescribed. Data shown are representative of three 
independent experiments. 
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Fig. 2. Concentration-dependent induction of MCP-I mRNA by 
PDGF-AB and -BB mesangial cells were incubated with PDGF-AB (n) 
or PDGF-BB ([]) at the concentrations indicated for 2 h. Northern blot 
analysis was performed as escribed. 
and IL-lfl persisted (Fig. 3). Even after 16 h, when PDGF by 
itself no longer had any effect on MCP-1 mRNA levels, coincu- 
bation still led to enhanced MCP-1 mRNA levels (Fig. 4). A 
similar interaction was also observed with 5-HT and IL-lfl: a 
synergistic increase in MCP-1 mRNA induction was observed 
after 16 h, at a time when serotonin by itself was without effect 
(data not shown). Induction of MCP-1 mRNA by TNFm an- 
other inflammatory cytokine, followed similar kinetics as ob- 
served with IL-1B. Coincubation of mesangial cells with TNFc~ 
and PDGF synergistically enhanced MCP-1 mRNA expression 
(Fig. 5). 
In order to investigate whether PDGF or IL-1]~ induced 
global upregulation of inducible genes related to inflammation 
we determined the mRNA expression of cyclooxygenase-2 
(prostaglandin G/H synthase, PGHS-2). The mRNA of this 
enzyme was upregulated by PDGF, but not by IL-lfl. When 
PDGF was added together with IL-lfl, cyclooxygenase expres- 
sion was not further enhanced (Fig. 5). 
3.3. MCP-1 mRNA stability 
mRNA stability was determined in the presence of the inhib- 
itor of transcription actinomycin D (10 pg/ml). Coincubation 
of mesangial cells with PDGF and IL-lfl increased the apparent 
half life of MCP-1 compared with the half life in the presence 
of either stimulus alone (Fig. 6). 
4. Discussion 
Recruitment of monocytic ells from the circulation to in- 
flamed or injured tissue sites such as in glomerulonephritis has 
been observed in many forms of glomerular disease. Among 
other factors, MCP-1, which is secreted from activated me- 
sangial cells, has been postulated to be involved as a chemo- 
attractant of monocytes to the glomerulus [22]. Thus far, 
interleukin-1 (IL-1), tumor necrosis factor cz (TNFcz) [12,13], 
tbrombin [23], interferon ~ [24] and immune complexes [25] 
have been shown to induce MCP-I mRNA expression i  me- 
sangial cells. Since PDGF seems to be critically involved in the 
pathogenesis of various types of glomerular inflammation 
[10,11], we investigated the effect of PDGF alone and in combi- 
nation with IL-lfl on the expression of MCP-1 mRNA. 
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MCP-1 mRNA levels were very low in unstimulated me- 
sangial cells, but were significantly enhanced in the presence of 
cycloheximide (CHX). Induction by CHX is generally inter- 
preted as mRNA stabilization due to the reduced synthesis of 
RNases. mRNA stabilization by CHX is typical for immediate 
early genes, the expression of which is independent of de novo 
protein synthesis. MCP-1 was originally identified as an imme- 
diate early gene in fibroblasts and CHX-dependent MCP-1 
mRNA expression was also observed in smooth muscle cells 
and endothelial cells [26,27]. Regulation by CHX, however, 
seems to be cell-specific, because in peripheral blood monocytes 
it caused inhibition of MCP-1 mRNA expression [26,27]. 
Induction of MCP-1 mRNA by PDGF-AB, -BB or serotonin 
(5-HT) and IL-lfl or TNF¢ followed different kinetics: pro- 
longed expression was observed by incubation with IL-lfl or 
TNFc~, whereas induction of MCP-1 by PDGF-AB and -BB or 
5-HT was transient. The apparent half lives of MCP-1 mRNA 
determined in the presence of the inhibitor of transcription, 
actinomycin D, seemed to contradict these kinetics: The appar- 
ent half life in the presence of IL-lfl was rather shorter than in 
the presence of PDGF. IL-lfl thus appeared to affect mRNA 
transcription, With respect o PDGF, additional mechanisms 
seem to be operative in the absence of actinomycin D, which 
counteract the mRNA stabilization observed in the presence of 
actinomycin D. A similar effect was previously observed in 
5-HT-stimulated mesangial cells, where the apparent half life 
of the inducible form of cyclooxygenase exceeded the transient 
expression [28]. Because of the low expression i  unstimulated 
cells, we could not determine the half life of MCP-1 mRNA in 
the absence of any stimulation. In vascular smooth muscle cells, 
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Fig. 4. Synergistic induction of MCP-1 mRNA by PDGF and IL-1]~ 
mesangial cells were incubated with PDGF-AB or -BB (20 ng/ml each) 
in the presence or absence of IL-lfl (2 U/ml) for 16 h. Data are repre- 
sentative of three experiments. 
which have many characteristics in common with mesangial 
cells, the apparent half life of MCP-1 mRNA was ~ 1 h and was 
prolonged by PDGF or angiotensin II [29]. 
Induction of MCP-1 mRNA was synergistic, when PDGF 
and IL-lfl were added together. This setting mi ht reflect the 
situation in vivo more closely, when both cytokines, which may 
be secrected by activated mesangial cells or by infiltrating plate- 
lets and monocytes, are present ogether in the inflamed glom- 
erulus. Synergism was also observed with PDGF and TNF~, 
a cytokine which shares many properties with IL-lfl. The syn- 
ergism was reflected at the level of mRNA stabilization, which 
was enhanced, when PDGF and IL-lfl acted together. Syner- 
gism between PDGF and IL- lfl was not a general phenomenon, 
as other proteins associated with inflammation such as the 
inducible cyclooxygenase-2, were not synergistically induced by 
PDGF and IL-lfl. 
We could thus show that two cytokines, which are involved 
in glomerular inflammatory reactions and which act via differ- 
ent intracellular signalling pathways, cooperate to enhance 
MCP-1 expression and thus might promote infiltration of mon- 
ocytic cells into inflamed tissues. 
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Fig. 3. Time course of PDGF- and IL-lfl-mediated MCP-1 mRNA 
induction mesangial cells were incubated with IL-lfl (I, • 2 U/ml), 
PDGF-BB (P, I ,  20 ng/ml) or both stimuli (I+P, *) for the times 
indicated. No MCP-1 mRNA signal was detected in untreated cells 
(Co). Data shown are representative of four experiments with similar 
results. 
Fig. 5. Specificity of synergistic MCP-1 mRNA induction mesangial 
cells were incubated with IL-lfl (2 U/ml), TNF~ (5 ng/ml) with or 
without PDGF-BB (20 ng/ml) for 2 h. Northern blot analysis was 
performed as described with cDNAs specific for MCP-I, cyclooxyge- 
nase-2 (prostaglandin G/H synthase-2, PGHS-2) and GAPDH. 
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Fig. 6. Apparent half life of MCP-1 mRNA mesangial cells were incu- 
bated with IL-lfl (e, 2 U/ml), PDGF-AB (I, 20 ng/ml) or both stimuli 
(A) for 2 h. Transcription was then inhibited byaddition of actinomycin 
D (10 pg/ml) and cells were further incubated for the times indicated. 
Northern blot analyses were quantitated by densitometry. Data are 
mean + S.E.M. of three to five experiments. 
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